Previous 10 | Next 10 |
Energous (NASDAQ:WATT) +35% granted FCC approval for unlimited Distance over-the-air wireless charging Edesa Biotech (NASDAQ:EDSA) +29% reports favorable mortality reductions in COVID-19 study InflaRx (NASDAQ:IFRX) +21% after EUR 43.7M vilobelimab development grant En...
Mortality reductions demonstrated across multiple patient groups Additional efficacy signals recorded in a broad range of mild to severe ARDS patients Company to focus on critically ill population for Phase 3 TORONTO, ON / ACCESSWIRE / October 19, 2021 / Edesa Biotech, Inc. ...
Edesa Biotech (NASDAQ:EDSA) was founded in 2015 by Dr. Par Nijhawan. Recently, the share volume of this Toronto-based drug developer surpassed 154 million. This was greater than 11 times the total number of shares outstanding. Accordingly, Edesa stock has gained quite a bit of popularit...
On Sep 20, EDSA reports positive p2 data. On a request of the DSMB (Data and Safety Monitoring Board), p2 portion of EDSA's ongoing p2/3 trial was "preemptively unblinded". Using Cox's Proportional Hazard Model, EDSA reports that patients treated with EB05, their monoclonal antibody c...
Gainers: Helbiz (NASDAQ:HLBZ) +128%. NanoViricides (NYSE:NNVC) +100%. ReWalk Robotics (NASDAQ:RWLK) +56%. Spire (NYSE:SPIR) +30%. Corvus (NASDAQ:CRVS) +29%. Inotiv (NASDAQ:NOTV) +26%. Candel (NASDAQ:CADL) +23%. Rockley (NYSE:RKLY) +19%. Protagonist (NASDAQ:PTGX) +18%. indie Semiconductor (NAS...
Gainers: ReWalk Robotics (NASDAQ:RWLK) +36%, NanoViricides (NYSE:NNVC) +36%, Inotiv (NASDAQ:NOTV) +27%, Solid Biosciences (NASDAQ:SLDB) +22%, eFFECTOR Therapeutics (NASDAQ:EFTR) +16%. Losers: Edesa Biotech (NASDAQ:EDSA) -25%, Verrica Pharmaceuticals (NASDAQ:...
FinancialBuzz.com’s latest The Buzz Show: Featuring Our Corporate News Recap on “ Edesa Biotech Announces Positive Phase 2 Data of Its Monoclonal Antibody in Hospitalized COVID-19 Patients ” Edesa Biotech, Inc. (NASDAQ: EDSA) ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Investors in Edesa Biotech (NASDAQ: EDSA ) and EDSA stock are perhaps the only investors grinning today. Amid a bloodbath in the markets, EDSA stock surged to nearly double yesterday’s close at today&...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +98%. Edesa (NASDAQ:EDSA) +68%. Sentage (NASDAQ:SNTG) +21%. Viveve (NASDAQ:VIVE) +19%. Aterian (NASDAQ:ATER) +15%. Atea Pharmaceuticals (NASDAQ:AVIR) +12%. Corvus (NASDAQ:CRVS) +13%. Five Star (NASDAQ:FVE) +12%. BEST (NYSE:BEST) +10%. Petros Pharmaceutic...
Gainers: ZIVO Bioscience (NASDAQ:ZIVO) +155%, Edesa Biotech (NASDAQ:EDSA) +34%, Atea Pharmaceuticals (NASDAQ:AVIR) +20%, Synlogic (NASDAQ:SYBX) +13%, Viveve Medical (NASDAQ:VIVE) +9%. Losers: BeyondSpring (NASDAQ:BYSI) -22%, Protagonist Therap...
News, Short Squeeze, Breakout and More Instantly...
This Phase 2 clinical study will evaluate paridiprubart (EB05) in hospitalized patients with acute respiratory distress syndrome (ARDS) due to a variety of causes. This BARDA-funded project is expected to complement Edesa's ongoing drug development activities in COVID-19 ARDS. Paridipru...
TORONTO, ON / ACCESSWIRE / May 10, 2024 / Edesa Biotech, Inc. (Nasdaq:EDSA), a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provid...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...